TLDR Secukinumab effectively treated a difficult case of folliculitis decalvans.
The letter reported a successful case of treating refractory folliculitis decalvans with secukinumab. Folliculitis decalvans is a chronic inflammatory condition leading to scarring hair loss, and it is often resistant to conventional treatments. The authors, Fathima Ferial Ismail and Rodney Sinclair, described the use of secukinumab, an IL-17A inhibitor, which resulted in significant clinical improvement in a patient who had not responded to other therapies. This case highlighted the potential of secukinumab as an effective treatment option for this challenging condition.
1 citations,
May 2015 in “Journal of The American Academy of Dermatology” Oral clindamycin and rifampicin are the most effective treatments for Folliculitis decalvans.
68 citations,
February 2015 in “Journal of the European Academy of Dermatology and Venereology” Early onset and pustules indicate severe hair follicle inflammation, and while antibiotics help, the condition often worsens after treatment stops.
1 citations,
September 2023 in “Dermatology and therapy” More research is needed to find the best treatment for dissecting cellulitis of the scalp.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
1 citations,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
1 citations,
July 2018 in “Elsevier eBooks” Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.
January 2023 in “European endocrinology” People with alopecia have a higher risk of thyroid cancer.
